Peripheral immunity is associated with the risk of incident dementia
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Central immunity components especially microglia in dementia have been well studied and corresponding immunotherapy gradually caught the attention. However, few studies focused on peripheral immunity and dementia. To address the issue, we examined the longitudinal association between incident dementia and peripheral immunity markers encompassing immune cell counts, and their derived ratios including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and lymphocyte-to-monocyte ratio (LMR), utilizing data of 361,653 participants from the UK Biobank (UKB). During a median follow-up of 8.99 years, 4239 participants developed dementia. The results revealed that increased innate immunity markers were associated with higher dementia risk (per SD increment hazard ratio [HR]; 95% confidence interval [CI] 1.14; 1.09-1.19 for neutrophils, 1.16; 1.11-1.20 for NLR and 1.11; 1.07-1.16 for SII), while increased adaptive immunity markers were associated with lower dementia risk (0.93; 0.90-0.97 for lymphocytes and 0.94; 0.90-0.98 for LMR). Our study pinpoints the differential role of innate and adaptive immunity in dementia incidence, which may provide some new perspectives in etiology and therapy of dementia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our results further corroborate previous findings.”
From Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants (2023) · cites this paper as [10]
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“MATERIALS AND METHODS Study population The UKB is a population-based cohort with over 500,000 participants aged 40–69 years when recruited in 2006–2010 [20].”
BackgroundBlood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · cited 1×
“BBB was found disrupted in neurodegenerative diseases and such breakdown may lead to pathogenic events like peripheral immune cells infiltration [12].”
BackgroundInnate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824 · cited 2×
“Adaptive immunity is characterized by two types of lymphocytes, T and B cells [16].”
BackgroundNichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412 · cited 1×
“INTRODUCTION Dementia is one of the top-ranked causes of death and disabilityadjusted life-years globally affecting around 50 million people, which brings substantial burden on patients, their caregivers, and national healthcare systems [1, 2].”
BackgroundInnate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865 · cited 3×
“Neutrophils depletion or blockade at the early stage could remarkably improve the CBF, reduce the neuropathology, and ameliorate memory deficits [25, 26].”
BackgroundInfluentialSystemic inflammation markers and cancer incidence in the UK Biobank
Nøst, T. H., Alcala, K., Urbarova, I., Byrne, K. S., Guida, F., Sandanger, T. M., & Johansson, M. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00752-6 · Cited by 526 · cited 2×
“Furthermore, these measurements derived ratios including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and lymphocyte-to-monocyte ratio (LMR), were thought to even better reflect the strength of peripheral immunity [17].”
BackgroundCruz Hernández, J. C., Bracko, O., Kersbergen, C. J., Muse, V., Haft-Javaherian, M., Berg, M., Park, L., Vinarcsik, L. K., Ivasyk, I., Rivera, D. A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0329-4 · Cited by 508
Baruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491 · cited 1×
“Depletion or pharmacological inhibition of Tregs in mice model presented enhanced clearance of Aβ plaque, mitigation of neuroinflammatory response, and reversal of cognitive decline [29].”
BackgroundMicroglia modulate neurodegeneration in Alzheimer’s and Parkinson’s diseases
Bartels, T., De Schepper, S., & Hong, S. (2020) · Science · doi:10.1126/science.abb8587 · Cited by 412 · cited 1×
“Microglia, the prominent central immunity component, interact with neurons in aging brain through complement-mediated synaptic loss and lysosomal degradation pathways [6, 7].”
BackgroundMarsh, S. E., Abud, E. M., Lakatos, A., Karimzadeh, A., Yeung, S. T., Davtyan, H., Fote, G. M., Lau, L., Weinger, J. G., Lane, T. E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525466113 · Cited by 411 · cited 1×
“One study found that the adaptive immune-deficient AD mice model that lacked T cells, B cells, and NK cells, which are called Rag5xFAD mice, exhibited a greater increase in Aβ pathology [27].”
BackgroundErickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378 · cited 1×
“However, current appreciation is that the immune privilege is real but relative [11].”
BackgroundRegulatory T cells delay disease progression in Alzheimer-like pathology
Dansokho, C., Ait Ahmed, D., Aid, S., Toly-Ndour, C., Chaigneau, T., Calle, V., Cagnard, N., Holzenberger, M., Piaggio, E., Aucouturier, P., et al. (2016) · Brain · doi:10.1093/brain/awv408 · Cited by 359
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications
Arranz, A. M., & De Strooper, B. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30490-3 · Cited by 334 · cited 1×
“Astroglia undergo morphological and functional alterations in senile pathology including reactive astrogliosis and atrophic asthenia, leading to gainof-function in neuroinflammation, calcium signaling and Aβ metabolism, and loss-of-function in local homeostasis and synapse formation [9].”
BackgroundThe Evaluation of Neutrophil-Lymphocyte Ratio in Alzheimers Disease
Kuyumcu, M. E., Yesil, Y., Oztürk, Z. A., Kizilarslanoglu, C., Etgül, S., Halil, M., Ulger, Z., Cankurtaran, M., & Ariogul, S. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000341583 · Cited by 245
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221 · cited 1×
“Approaches to modify central immunity by targeting the microglia markers, especially triggering receptor expressed on myeloid cells 2, is on the forefront of immunotherapies [8].”
BackgroundMicroglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia
Lall, D., & Baloh, R. H. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90607 · Cited by 175 · cited 1×
“Microglia, the prominent central immunity component, interact with neurons in aging brain through complement-mediated synaptic loss and lysosomal degradation pathways [6, 7].”
BackgroundA Comprehensive Update on Treatment of Dementia
Tisher, A., & Salardini, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1683408 · Cited by 168 · cited 1×
“Until now, there is only one Food and Drug Administration approved disease-modifying drug, aducanumab [3, 4], for Alzheimer’s dementia (AD) while no disease-modifying therapies recommended for other types of dementia [5].”
BackgroundRevisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162 · cited 1×
“Until now, there is only one Food and Drug Administration approved disease-modifying drug, aducanumab [3, 4], for Alzheimer’s dementia (AD) while no disease-modifying therapies recommended for other types of dementia [5].”
BackgroundControversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Rabinovici, G. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2111320 · Cited by 155 · cited 1×
“Until now, there is only one Food and Drug Administration approved disease-modifying drug, aducanumab [3, 4], for Alzheimer’s dementia (AD) while no disease-modifying therapies recommended for other types of dementia [5].”
BackgroundSaresella, M., Calabrese, E., Marventano, I., Piancone, F., Gatti, A., Calvo, M. G., Nemni, R., & Clerici, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091696 · Cited by 145 · cited 1×
“Consistent with genetic ablation, immunosuppression as a result of increased peripheral T regulatory cells (Tregs) also contributed to the progression of AD [28].”
BackgroundNi, H., Wang, Y., An, K., Liu, Q., Xu, L., Zhu, C., Deng, H., He, Q., Wang, T., Xu, M., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1391-2 · Cited by 139
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 127
Self-citationRembach, A., Watt, A. D., Wilson, W. J., Rainey‐Smith, S. R., Ellis, K. A., Rowe, C. C., Villemagne, V. L., Macaulay, S. L., Bush, A. I., Martins, R. N., et al. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.05.005 · Cited by 122
Oligodendroglial Cells in Alzheimer’s Disease
Butt, A. M., Rocha, I. C. D. L., & Rivera, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_12 · Cited by 109 · cited 1×
“The dysfunction of another important glia component, oligodendrocytes and their progenitor cells neuron-glial antigen 2 glia, would cause age-associated myelin loss and induce axon degeneration and neuronal death [10].”
Backgroundvan der Willik, K. D., Fani, L., Rizopoulos, D., Licher, S., Fest, J., Schagen, S. B., Ikram, M. K., & Ikram, M. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1454-z · Cited by 96 · cited 2×
“While a small prospective study clarified the longitudinal association between some of the peripheral immunity markers and dementia [19].”
BackgroundSpäni, C., Suter, T., Derungs, R., Ferretti, M. T., Welt, T., Wirth, F., Gericke, C., Nitsch, R. M., & Kulic, L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0251-x · Cited by 88 · cited 1×
“However, there are also some contradictory findings showing that adaptive immunity deficiency can reduce Aβ pathology in AD mice model [30] and Tregs play a beneficial role in AD pathophysiology at an early stage [31].”
BackgroundAltered peripheral profile of blood cells in Alzheimer disease: A hospital-based case-control study
Chen, S.-H., Bu, X.-L., Jin, W.-S., Shen, L.-L., Wang, J., Zhuang, Z.-Q., Zhang, T., Zeng, F., Yao, X.-Q., Zhou, H.-D., et al. (2017) · Medicine · doi:10.1097/md.0000000000006843 · Cited by 64
Self-citationKara, S. P., Altunan, B., & Unal, A. (2022) · Neurological Sciences · doi:10.1007/s10072-021-05507-5 · Cited by 63 · cited 1×
“Previous retrospective study did not establish the relationship of peripheral immune cells and AD [18].”
Kalelioğlu, T., Yürüyen, M., Gültekin, G., Yavuzer, H., Öztürk, Y., Kurt, M., Topçu, Y., Döventaş, A., & Emül, M. (2017) · Psychogeriatrics · doi:10.1111/psyg.12260 · Cited by 50
Fani, L., Ahmad, S., Ikram, M. K., Ghanbari, M., & Ikram, M. A. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12212 · Cited by 30 · cited 1×
“Further evidence indicated that peripheral immunity contributed to Aβ and tau metabolism and shaped inflammatory responses in AD [13, 14].”
Background
Research works printed but not linked: 1
- Chen SH, Bu XLE, Jin WS, Shen LL, Wang J, Zhuang ZQ, et al. Altered peripheral profile of blood cells in Alzheimer disease. Medicine. 2017;96:1–7.
Cited by
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Self-citationYang, X., Zhao, S., Wang, S., Cao, X., Xu, Y., Yan, M., Pang, M., Yi, F., & Wang, H. (2023) · BMC Medicine · doi:10.1186/s12916-023-02770-5 · Cited by 92
Self-citationQiang, Y., Deng, Y., Zhang, Y.-R., Wang, H.-F., Zhang, W., Dong, Q., Feng, J., Cheng, W., & Yu, J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13088 · Cited by 93
Self-citationQin, P., Ho, F. K. W., Celis-Morales, C. A., & Pell, J. P. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02721-9 · Cited by 94
“Evidence is accumulating of the associations of these new biomarkers with cancer [3], dementia [4], cerebrovascular plaques [5], arrhythmias [6], and premature death [7].”
Zhong, X., Qiang, Y., Wang, L., Zhang, Y., Li, J., Feng, J., Cheng, W., Tan, L., & Yu, J. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02683-0 · Cited by 55
“More research is needed to further elucidate the speci fi c neuroin fl ammatory mechanisms that give rise to speci fi c disorders.”
BackgroundSelf-citation
Metadata
- Authors
- Zhang, Y.-R., Wang, J.-J., Chen, S.-F., Wang, H.-F., Li, Y.-Z., Ou, Y.-N., Huang, S.-Y., Chen, S.-D., Cheng, W., Feng, J.-F., Dong, Q., & Yu, J.-T.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Qingdao University (CN)
- Fudan University (CN)
- Corresponding author
- Yu, Jin-Tai
- Venue
- Molecular Psychiatry
- Published
- 2022-01-25
- Volume
- 27
- Issue
- 4
- Pages
- 1956-1962
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W4210426755
- Cited by
- 114
- References
- 32
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 33 · 2023: 19 · 2022: 9
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (91849126)
- Science and Technology Commission of Shanghai Municipality (No.2018SHZDZX01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- peripheral immunity, dementia, incident dementia risk, innate immunity, adaptive immunity, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, immune cell counts, inflammation, dementia etiology, dementia treatment
- MeSH terms
- Blood Platelets, Dementia, Humans, Inflammation, Lymphocytes, Neutrophils, Retrospective Studies, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.